← 返回前沿论文

TIL(肿瘤浸润淋巴细胞)介导的针对患者来源肺癌类器官细胞毒作用的转录组分析

英文原题:Transcriptome profiling of tumor-infiltrating lymphocyte-mediated cytotoxicity against patient-derived lung cancer organoids.

PubMed 2025/11/23(内容时间) Commun Biol Q1 · IF 5.8(JCR 2025)

研究概要

非小细胞肺癌(NSCLC)是癌症死亡的主要原因之一,利用TIL(肿瘤浸润淋巴细胞)(TILs)的疗法显示出巨大前景。

中文摘要

非小细胞肺癌(NSCLC)是癌症死亡的主要原因之一,利用TIL(肿瘤浸润淋巴细胞)(TILs)的疗法展现出巨大前景。然而,定义有效TIL介导反应的分子特征仍鲜有阐明。在此,我们建立了一个患者来源类器官与自体TIL共培养平台,证明扩增的TILs对NSCLC类器官介导强效、特异性的细胞毒性。这种功能性反应与T细胞状态从增殖型向效应记忆表型的关键转变相关,并涉及激活关键信号网络,包括TNF和IL-17通路。此外,T细胞受体(TCR)分析证实,扩增过程选择性富集肿瘤相关克隆型,从而形成更为集中的 repertoire。本研究阐明了有效抗肿瘤免疫反应的转录和克隆特征,为指导下一代个性化TIL疗法提供了稳健框架。

展开英文摘要原文

Non-small cell lung cancer (NSCLC) is a leading cause of cancer mortality, and therapies utilizing tumor-infiltrating lymphocytes (TILs) show significant promise. However, molecular signatures defining a productive TIL-mediated response remain poorly characterized. Here, we establish a patient-derived organoid and autologous TIL co-culture platform to show that expanded TILs mediate potent, specific cytotoxicity against NSCLC organoids. This functional response is associated with a crucial shift in T-cell states from proliferative towards effector memory phenotypes and involves activating key signaling networks, including the TNF and IL-17 pathways. Furthermore, T-cell receptor (TCR) analysis confirms the expansion process selectively enriches tumor-associated clonotypes, resulting in a more focused repertoire. This work delineates the transcriptional and clonal signatures of an effective anti-tumor immune response, providing a robust framework to guide next-generation personalized TIL therapies.

论文信息

作者
Qin Z、Zhang H、Li Y、Yang J、Liu H、Guan Z、Hou Q、Du H
第一作者单位
Department of Thoracic Surgery, Peking University Shenzhen Hospital, Shenzhen, China.China
通讯作者单位
Department of Thoracic Surgery, Peking University Shenzhen Hospital, Shenzhen, China. 409985846@qq.com.China
期刊
Communications biology2025 Nov 23
原文标识
PubMed 41276656 · DOI 10.1038/s42003-025-09188-0